항핵항체 검사 시장 규모, 점유율 및 동향 분석 리포트 : 제품별, 검사 기법별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Antinuclear Antibody Test Market Summary

The global antinuclear antibody test market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.47 billion by 2033, growing at a CAGR of 13.49% from 2025 to 2033. The market growth is accelerated by advancements in antinuclear antibody test (ANA) diagnostics, as it shifts toward standardization and high-throughput autoimmune testing.

The industry is increasingly adopting AI-enabled immunofluorescence platforms that enhance accuracy, consistency, and workflow efficiency.

For instance, in August 2025, Journal of Clinical Medicine demonstrated the value of AI-assisted ANA IIFT, showing good concordance with classical visual interpretation and significantly improving reproducibility in pattern recognition, especially at clinically relevant cut-offs. These findings reinforce AI's emerging role in minimizing observer variability and supporting reliable ANA screening. In parallel, digital IFA imaging solutions are reshaping routine diagnostics.

For instance, in January 2022, ZEUS Scientific, Inc. launched the dIFine platform with an integrated HEp-2 Pattern Atlas, providing automated slide scanning, intelligent pattern recognition, and side-by-side reference image comparison to elevate standardization and operator. AI-driven interpretation, automated digital microscopy, and improved pattern-classification tools are all improving ANA diagnostics, allowing laboratories to meet rising autoimmune disease testing demand with greater precision and operational efficiency.

Global Antinuclear Antibody Test Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antinuclear antibody test market report based on product, test technique, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Assay Kits
• Systems
• Software & Services
• Test Technique Outlook (Revenue, USD Million, 2021 - 2033)
• ELISA
• Immunofluorescence Assay
• Multiplex Assay
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Sjogren's Syndrome
• Scleroderma
• Other Diseases
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinical Laboratories
• Physician Office Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product
    • 1.1.1.2. Test Technique Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product
• 2.3. Test Technique Snapshot
• 2.4. Application Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising prevalence of autoimmune diseases
  • 3.4.2. Advancements in antinuclear antibody diagnostic technologies
  • 3.4.3. Growing detection of asymptomatic and subclinical autoimmunity
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of advanced systems and skilled workforce requirements
  • 3.5.2. Variability in test interpretation and lack of standardization
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Product Estimates & Trend Analysis

• 4.1. Antinuclear Antibody Test Market: Product Movement Analysis
• 4.2. Reagents & Assay Kits
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Systems
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Software & Services
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Test Technique Estimates & Trend Analysis

• 5.1. Antinuclear Antibody Test Market: Test Technique Movement Analysis
• 5.2. ELISA
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Immunofluorescence Assay
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Multiplex Assay
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Application Estimates & Trend Analysis

• 6.1. Antinuclear Antibody Test Market: Application Movement Analysis
• 6.2. Rheumatoid Arthritis
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Systemic Lupus Erythematosus
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Sjogren's Syndrome
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Scleroderma
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Other Diseases
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. End Use Estimates & Trend Analysis

• 7.1. Antinuclear Antibody Test Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Clinical Laboratories
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Physician Office Laboratories
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Antinuclear Antibody Test Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Antinuclear Antibody Test Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Product Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. Abbott
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Bio-Rad Laboratories, Inc.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Erba Mannheim
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Trinity Biotech Plc.
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Thermo Fisher Scientific, Inc.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Antibodies Incorporated
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. QuidelOrtho Corporation
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. ZEUS Scientific, Inc.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Merck KgaA
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Revvity
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. EUROIMMUN Medizinische Labordiagnostika AG
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Immuno Concepts NA Ltd.
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. ORGENTEC
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. Transasia Bio-Medicals
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Financial Performance
    • 9.5.14.3. Product Benchmarking
    • 9.5.14.4. Strategic Initiatives